KK Women's and Children's Hospital (KKH) Autologous Umbilical Cord Blood Reinfusion for the Treatment of Autism
Safety and Efficacy (Auto-UCB-ASD 01)* Clinical Trial Update
Cordlife Group is honoured to play a part in the clinical trial run by KKH for the treatment of autism through autologous umbilical cord blood reinfusion. This clinical trial is the first of its kind to be conducted in Singapore.
Cordlife’s Cord Blood Releases For KKH Autism Trial
As a Group, Cordlife has released cord blood for twelve (12) clients who participated in the clinical trial. All of our clients were successfully infused with their own cord blood as part of the trial. Prior to each release, quality assurance test was performed and the results met the trial requirement.
| No. | Year of Release | Banked with | Total Nucleated Cell Count | % of units used | Storage Time (Months) | Storage Country |
|---|---|---|---|---|---|---|
| 1 | 2019 | Cordlife Singapore | 980 million | 100% | 78.4 | Singapore |
| 2 | 2019 | Cordlife Singapore | 733 million | 100% | 67.7 | Singapore |
| 3 | 2019 | Cordlife Singapore | 1.03 billion | 100% | 47.7 | Singapore |
| 4 | 2019 | Cordlife Singapore | 1.11 billion | 100% | 54.4 | Singapore |
| 5 | 2019 | Cordlife Singapore | 912 million | 80% | 59.8 | Singapore |
| 6 | 2020 | Cordlife Singapore | 1.02 billion | 100% | 59.7 | Singapore |
| 7 | 2020 | Cordlife Singapore | 1.07 billion | 100% | 52.3 | Singapore |
| 8 | 2020 | Cordlife Singapore | 740 million | 100% | 60.0 | Singapore |
| 9 | 2021 | Cordlife Philippines | 622 million | 100% | 49.4 | Philippines |
| 10 | 2021 | Cordlife Singapore | 407 million | 100% | 45.7 | Singapore |
| 11 | 2021 | Cordlife Singapore | 441 million | 100% | 65.1 | Singapore |
| 12 | 2021 | Cordlife Singapore | 593 million | 100% | 63.2 | Singapore |
Last updated on 30 Sept 2021
About KK Women’s And Children’s Hospital (KKH)
Established in 1858, KKH is Singapore's leading hospital specialising in Obstetrics, Gynaecology, Paediatrics and Neonatology. Today, the 830-bed hospital is a referral centre providing tertiary services to manage high-risk conditions in women and children in Singapore.
More About Clinical Trials
Purpose
To determine if Haematopoietic stem cells in Cord blood can improve ASD symptoms.
Duration
18 to 20 months (7 study visits)
Eligibility Criteria
Age 24 -to 60 months.
Confirmed clinical DSM-5.
Have autologous cord blood stored with a cord blood bank when the child was born.
What is involved?
Two blood tests and a day-case admission to KKH for the child’s cord blood to be reinfused back to him/her.
Repeated psychological tests on the child to assess ASD severity, behaviour, adaptive skills and IQ before and after cord blood infusion.
Eye-tracking assessments on the child before and after cord blood infusion.
Note: Enrolment for the trial has closed since 1 February 2021.
*Reference: Clinical Trials Register. Health Science Authority Website. https://www.hsa.gov.sg/clinical-trials/clinical-trials-register. Last accessed May 17, 2021.
Subscribe to our newsletter
PRIVACY POLICY
TERMS AND CONDITIONS